148 related articles for article (PubMed ID: 3882092)
1. Inhibition of ribonucleotide reductase by antitumor agents related to levodopa and dopamine.
FitzGerald GB; Wick MM
Biochem Pharmacol; 1985 Feb; 34(3):353-60. PubMed ID: 3882092
[TBL] [Abstract][Full Text] [Related]
2. Sequential inhibitory effects of antitumor agents related to levodopa and dopamine upon DNA synthetic enzymes.
Fitzgerald GB; Wick MM
Biochem Pharmacol; 1986 Jan; 35(2):271-5. PubMed ID: 3510622
[TBL] [Abstract][Full Text] [Related]
3. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC
Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of biologic reducing agents related to 3,4-dihydroxybenzylamine: dihydroxybenzaldehyde, dihydroxybenzaldoxime, and dihydroxybenzonitrile.
Wick MM; FitzGerald GB
J Pharm Sci; 1987 Jul; 76(7):513-5. PubMed ID: 3312571
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N'-aminoguanidine derivatives.
Cory JG; Carter GL; Bacon PE; T'ang A; Lien EJ
Biochem Pharmacol; 1985 Aug; 34(15):2645-50. PubMed ID: 3893440
[TBL] [Abstract][Full Text] [Related]
6. Structural aspects of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of L1210 cell growth and ribonucleotide reductase activity.
Cory JG; Cory AH; Raber NK; Narayanan A; Schneller SW
Adv Enzyme Regul; 1993; 33():129-40. PubMed ID: 8356905
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives.
Matsumoto M; Fox JG; Wang PH; Koneru PB; Lien EJ; Cory JG
Biochem Pharmacol; 1990 Oct; 40(8):1779-83. PubMed ID: 2242014
[TBL] [Abstract][Full Text] [Related]
8. Drug action on ribonucleotide reductase.
Cory JG; Carter GL
Adv Enzyme Regul; 1985; 24():385-401. PubMed ID: 3915189
[TBL] [Abstract][Full Text] [Related]
9. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
Carter GL; Cory JG
Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
[TBL] [Abstract][Full Text] [Related]
10. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
Cory JG; Carter GL
Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ribonucleotide reductase by naturally occurring quinols from spores of Agaricus bisporus.
FitzGerald GB; Rosowsky A; Wick MM
Biochem Biophys Res Commun; 1984 May; 120(3):1008-14. PubMed ID: 6375659
[TBL] [Abstract][Full Text] [Related]
12. Properties of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of mammalian ribonucleotide reductase.
Weckbecker G; Lien EJ; Cory JG
Biochem Pharmacol; 1988 Feb; 37(3):529-34. PubMed ID: 3276327
[TBL] [Abstract][Full Text] [Related]
13. Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.
Tihan T; Elford HL; Cory JG
Adv Enzyme Regul; 1991; 31():71-83. PubMed ID: 1877400
[TBL] [Abstract][Full Text] [Related]
14. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide.
Kwon NS; Stuehr DJ; Nathan CF
J Exp Med; 1991 Oct; 174(4):761-7. PubMed ID: 1717630
[TBL] [Abstract][Full Text] [Related]
16. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase.
Carter GL; Cory JG
Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151
[TBL] [Abstract][Full Text] [Related]
17. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory AH; Sato A; Thompson DP; Cory JG
Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells.
Chitambar CR; Narasimhan J; Guy J; Sem DS; O'Brien WJ
Cancer Res; 1991 Nov; 51(22):6199-201. PubMed ID: 1933878
[TBL] [Abstract][Full Text] [Related]
19. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
Sato A; Carter GL; Bacon PE; Cory JG
Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
[TBL] [Abstract][Full Text] [Related]
20. Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture.
Sato A; Carter GL; Bacon PE; Cory JG
Adv Enzyme Regul; 1983; 21():259-70. PubMed ID: 6400064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
